GPT and metabolic dysfunction-associated steatotic liver disease: Zhang Liangdeng et al. [18] conducted 10 randomized controlled trials (RCTs) with 802 NAFLD subjects, and a meta-analysis showed that the total cholesterol, low-density lipoprotein, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels decreased compared with those in a control group following Chaihu-Shugan-San treatment.